agenT-797 - (C-1300-02)

August 6, 2026: MiNK Therapeutics (NSDAQ: INKT) reported initial observations from the ongoing randomized Phase 2 C-1300-02 trial of agenT-797 in severe hypoxemic pneumonia/ARDS and acute lung injury/critical illness. In the first treated patients, all were alive and afebrile at Day 28, with improved oxygenation, hemodynamics, and mental status, plus removal from ventilator and vasopressor support. Microbiological data indicated control of baseline infections, and serum/bronchoalveolar lavage analyses showed reduced inflammatory markers and biological changes associated with immune recovery, epithelial repair, and pulmonary vascular recovery. No major serious adverse events attributed to agenT-797 were reported in these initial patients.

The data were presented August 6, 2026 at the Military Health System Research Symposium (MHSRS) in a session titled “Randomized Phase 2 of agenT-797 as a Pathogen-Agnostic Treatment of Hypoxemic Pneumonia/ARDS in Austere and Conflict Environments.”

The study compares agenT-797 plus standard of care versus placebo plus standard of care in adults meeting Global ARDS criteria. Enrollment is ongoing at First Lviv Territorial Medical Union in Ukraine, with U.S. site expansion underway. Preliminary data are expected in 2H 2026, with additional data expected in early 2027.